Cargando…
Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma
Malignant pleural mesothelioma (MPM) is an aggressive tumor with an unfavorable prognosis. The standard therapeutic approaches are limited to surgery, chemotherapy, and radiotherapy. Because the consequent clinical outcome is often unsatisfactory, a different approach in MPM treatment is required. S...
Autores principales: | Sato, Hiroki, Sakaguchi, Masakiyo, Yamamoto, Hiromasa, Tomida, Shuta, Aoe, Keisuke, Shien, Kazuhiko, Yoshioka, Takahiro, Namba, Kei, Torigoe, Hidejiro, Soh, Junichi, Tsukuda, Kazunori, Tao, Hiroyuki, Okabe, Kazunori, Miyoshi, Shinichiro, Pass, Harvey I., Toyooka, Shinichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833371/ https://www.ncbi.nlm.nih.gov/pubmed/29362358 http://dx.doi.org/10.1038/s41389-017-0017-3 |
Ejemplares similares
-
Therapeutic strategies for afatinib‐resistant lung cancer harboring HER2 alterations
por: Torigoe, Hidejiro, et al.
Publicado: (2018) -
Antitumor activity of pan‐HER inhibitors in HER2‐positive gastric cancer
por: Yoshioka, Takahiro, et al.
Publicado: (2018) -
Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway
por: Ohtsuka, Tomoaki, et al.
Publicado: (2016) -
Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features
por: Sato, Hiroki, et al.
Publicado: (2017) -
Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations
por: Ogoshi, Yusuke, et al.
Publicado: (2019)